Session: Poster Session B Abstract title: Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, ...

为解决胰腺癌免疫治疗难题，约翰霍普金斯大学医学院等机构的研究人员开展了胰腺癌肝肺转移小鼠模型对 IL-1β 阻断反应的研究。结果显示联合疗法效果因转移部位而异，该研究为胰腺癌免疫治疗提供新思路，值得科研人员一读。